Product Description
Mechanisms of Action: Potassium Channel Blocker,Rnase Inhibitor,mAChR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Armadale Health Service
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HS-21-00540 | N/A |
Not yet recruiting |
Tobacco Use Disorder |
2018-11-01 |
Recent News Events
Date |
Type |
Title |
|---|